Submission Of Status Of Investor Complaints Under Regulation 13(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Quarter Ended 31.03.2017

Dated: 07th April, 2017 To, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Fort Mumbai-400001 Email ID: [email protected] Ref: Genomic Valley Biotech Limited (539206/ GVBL) Sub: Submission of Status of Investor Complaints under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter ended 31.03.2017 Dear Sir/Madam, Pursuant to the Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find below the status of Investor Complaints for the quarter ended 31.03.2017. PARTICULAR OF COMPLAINTS STATUS OF COMPLAINTS Pending at the beginning of the quarter Nil Received during the quarter Nil Disposed of during the quarter Nil Remaining unresolved at the end of the quarter Nil Kindly take the same into your records. Thanking you. Yours faithfully, For and on behalf of Genomic Valley Biotech Limited Hitesh Kumar Company Secretary & Compliance officer

Pdf Link: Submission Of Status Of Investor Complaints Under Regulation 13(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Quarter Ended 31.03.2017

Source : BSE - www.bseindia.com

Published on April 07, 2017
TOPICS

Related

This article is closed for comments.
Please Email the Editor